Literature DB >> 22019111

[Extrapolating the NNT jeopardises biostatistics and leads to immortality].

Luis Palomo, Galo Sánchez-Robles.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22019111      PMCID： PMC7025177          DOI： 10.1016/j.aprim.2011.06.007

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  4 in total

Review 1.  Calculating the number needed to treat for trials where the outcome is time to an event.

Authors:  D G Altman; P K Andersen
Journal:  BMJ       Date:  1999-12-04

2.  An assessment of clinically useful measures of the consequences of treatment.

Authors:  A Laupacis; D L Sackett; R S Roberts
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

3.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

4.  Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities.

Authors:  Wolfgang Koenig; Paul M Ridker
Journal:  Eur Heart J       Date:  2010-10-22       Impact factor: 29.983
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.